{"transactions":[{"id":1881560,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Non-qualified Stock Options","published_at":"2023-05-23T12:06:26.000Z","date":"2023-05-19","kind":"exercise","planned":false,"acquired":false,"shares":4300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vested in three equal annual installments beginning on the date reflected in this column."}],"balance_after":0,"derivative":{"exercise_price":182.51,"exercise_date":"2021-02-04","expiration_date":"2030-02-03","underlying":"Common Stock","underlying_shares":4300},"source":{"system":"sec-edgar","filing":"0001127602-23-016525","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760223016525/form4.xml","form_type":"4"}},{"id":1881559,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2023-05-23T12:06:26.000Z","date":"2023-05-19","kind":"sale","planned":false,"acquired":false,"shares":4300,"price":216.9086,"value":932706.98,"ownership":{"direct":true},"balance_after":12946,"source":{"system":"sec-edgar","filing":"0001127602-23-016525","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760223016525/form4.xml","form_type":"4"}},{"id":1881558,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2023-05-23T12:06:26.000Z","date":"2023-05-19","kind":"exercise","planned":false,"acquired":true,"shares":4300,"price":182.51,"value":784793.0,"ownership":{"direct":true},"balance_after":17246,"source":{"system":"sec-edgar","filing":"0001127602-23-016525","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760223016525/form4.xml","form_type":"4"}},{"id":1933124,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2023-04-03T14:13:05.000Z","date":"2023-03-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":2886,"price":224.7,"value":648484.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Stock withholding to satisfy tax withholding obligations."}],"balance_after":12946,"source":{"system":"sec-edgar","filing":"0001127602-23-011750","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760223011750/form4.xml","form_type":"4"}},{"id":1933123,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2023-04-03T14:13:05.000Z","date":"2023-03-30","kind":"grant","planned":false,"acquired":true,"shares":6763,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares acquired on March 30, 2023, pursuant to a performance award granted on February 4, 2020, relating to performance during the three-year period ended December 31, 2022."}],"balance_after":15832,"source":{"system":"sec-edgar","filing":"0001127602-23-011750","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760223011750/form4.xml","form_type":"4"}},{"id":1997069,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Non-qualified Stock Options","published_at":"2023-02-23T14:54:27.000Z","date":"2023-02-21","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested in three equal annual installments beginning on the date reflected in this column."}],"balance_after":4300,"derivative":{"exercise_price":182.51,"exercise_date":"2021-02-04","expiration_date":"2030-02-03","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001127602-23-006642","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760223006642/form4.xml","form_type":"4"}},{"id":1997068,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2023-02-23T14:54:27.000Z","date":"2023-02-21","kind":"sale","acquired":false,"shares":8000,"price":250.5844,"value":2004675.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price of $250.5844 per share represents a weighted average of sales prices ranging from $250.44 to $250.79 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a securityholder of the issuer, full information regarding the number of shares purchased or sold at each separate price."}],"balance_after":9069,"source":{"system":"sec-edgar","filing":"0001127602-23-006642","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760223006642/form4.xml","form_type":"4"}},{"id":1997067,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2023-02-23T14:54:27.000Z","date":"2023-02-21","kind":"exercise","acquired":true,"shares":3000,"price":182.51,"value":547530.0,"ownership":{"direct":true},"balance_after":17069,"source":{"system":"sec-edgar","filing":"0001127602-23-006642","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760223006642/form4.xml","form_type":"4"}},{"id":2017675,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Restricted Stock Unit","published_at":"2023-02-14T19:57:47.000Z","date":"2023-02-11","kind":"exercise","acquired":false,"shares":483,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"This number reflects the aggregate number of Restricted Stock Units held by the reporting person."}],"balance_after":3001,"derivative":{"underlying":"Common Stock","underlying_shares":483},"source":{"system":"sec-edgar","filing":"0001127602-23-005103","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760223005103/form4.xml","form_type":"4"}},{"id":2017674,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2023-02-14T19:57:47.000Z","date":"2023-02-13","kind":"tax_withholding","acquired":false,"shares":142,"price":248.13,"value":35234.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Stock withholding to satisfy tax withholding obligations."}],"balance_after":14069,"source":{"system":"sec-edgar","filing":"0001127602-23-005103","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760223005103/form4.xml","form_type":"4"}},{"id":2017673,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2023-02-14T19:57:47.000Z","date":"2023-02-11","kind":"exercise","acquired":true,"shares":483,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock."}],"balance_after":14211,"source":{"system":"sec-edgar","filing":"0001127602-23-005103","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760223005103/form4.xml","form_type":"4"}},{"id":2025271,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Non-qualified Stock Options","published_at":"2023-02-09T17:02:35.000Z","date":"2023-02-07","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests in three equal annual installments beginning on the date reflected in this column."}],"balance_after":5000,"derivative":{"exercise_price":247.24,"exercise_date":"2024-02-07","expiration_date":"2033-02-06","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001127602-23-004109","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760223004109/form4.xml","form_type":"4"}},{"id":2025270,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Restricted Stock Unit","published_at":"2023-02-09T17:02:35.000Z","date":"2023-02-07","kind":"grant","acquired":true,"shares":1590,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Restricted Stock Units vest in three equal annual installments beginning on February 7, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Restricted Stock Units vest in three equal annual installments beginning on February 7, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This number reflects the aggregate number of Restricted Stock Units held by the reporting person."}],"balance_after":3484,"derivative":{"underlying":"Common Stock","underlying_shares":1590},"source":{"system":"sec-edgar","filing":"0001127602-23-004109","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760223004109/form4.xml","form_type":"4"}},{"id":2029279,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Restricted Stock Unit","published_at":"2023-02-07T19:51:34.000Z","date":"2023-02-04","kind":"exercise","acquired":false,"shares":560,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Restricted Stock Units vested in three equal annual installments beginning on February 4, 2021 and are now fully vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Restricted Stock Units vested in three equal annual installments beginning on February 4, 2021 and are now fully vested."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"This number reflects the aggregate number of Restricted Stock Units held by the reporting person."}],"balance_after":1894,"derivative":{"underlying":"Common Stock","underlying_shares":560},"source":{"system":"sec-edgar","filing":"0001127602-23-003703","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760223003703/form4.xml","form_type":"4"}},{"id":2029278,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2023-02-07T19:51:34.000Z","date":"2023-02-06","kind":"tax_withholding","acquired":false,"shares":164,"price":244.5,"value":40098.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Stock withholding to satisfy tax withholding obligations."}],"balance_after":13728,"source":{"system":"sec-edgar","filing":"0001127602-23-003703","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760223003703/form4.xml","form_type":"4"}},{"id":2029277,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2023-02-07T19:51:34.000Z","date":"2023-02-04","kind":"exercise","acquired":true,"shares":560,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock."}],"balance_after":13892,"source":{"system":"sec-edgar","filing":"0001127602-23-003703","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760223003703/form4.xml","form_type":"4"}},{"id":2031109,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Restricted Stock Unit","published_at":"2023-02-06T20:45:49.000Z","date":"2023-02-02","kind":"exercise","acquired":false,"shares":443,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 2, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 2, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"This number reflects the aggregate number of Restricted Stock Units held by the reporting person."}],"balance_after":2454,"derivative":{"underlying":"Common Stock","underlying_shares":443},"source":{"system":"sec-edgar","filing":"0001127602-23-003532","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760223003532/form4.xml","form_type":"4"}},{"id":2031108,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2023-02-06T20:45:49.000Z","date":"2023-02-02","kind":"tax_withholding","acquired":false,"shares":141,"price":254.99,"value":35953.59,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Stock withholding to satisfy tax withholding obligations."}],"balance_after":13332,"source":{"system":"sec-edgar","filing":"0001127602-23-003532","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760223003532/form4.xml","form_type":"4"}},{"id":2031107,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2023-02-06T20:45:49.000Z","date":"2023-02-02","kind":"exercise","acquired":true,"shares":443,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock."}],"balance_after":13473,"source":{"system":"sec-edgar","filing":"0001127602-23-003532","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760223003532/form4.xml","form_type":"4"}},{"id":2126315,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Restricted Stock Unit","published_at":"2022-11-03T21:00:04.000Z","date":"2022-11-01","kind":"exercise","acquired":false,"shares":2007,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Restricted Stock Units vested in three equal annual installments beginning on November 1, 2020 and are now fully vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Restricted Stock Units vested in three equal annual installments beginning on November 1, 2020 and are now fully vested."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"This number reflects the aggregate number of Restricted Stock Units held by the reporting person."}],"balance_after":2897,"derivative":{"underlying":"Common Stock","underlying_shares":2007},"source":{"system":"sec-edgar","filing":"0001127602-22-024921","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760222024921/form4.xml","form_type":"4"}},{"id":2126314,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2022-11-03T21:00:04.000Z","date":"2022-11-01","kind":"tax_withholding","acquired":false,"shares":892,"price":222.56,"value":198523.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Stock withholding to satisfy tax withholding obligations."}],"balance_after":13030,"source":{"system":"sec-edgar","filing":"0001127602-22-024921","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760222024921/form4.xml","form_type":"4"}},{"id":2126313,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2022-11-03T21:00:04.000Z","date":"2022-11-01","kind":"exercise","acquired":true,"shares":2007,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock."}],"balance_after":13922,"source":{"system":"sec-edgar","filing":"0001127602-22-024921","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760222024921/form4.xml","form_type":"4"}},{"id":2315885,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2022-03-29T16:04:20.000Z","date":"2022-03-28","kind":"tax_withholding","acquired":false,"shares":1648,"price":276.42,"value":455540.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Stock withholding to satisfy tax withholding obligations."}],"balance_after":11915,"source":{"system":"sec-edgar","filing":"0001127602-22-010503","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760222010503/form4.xml","form_type":"4"}},{"id":2315884,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2022-03-29T16:04:20.000Z","date":"2022-03-27","kind":"grant","acquired":true,"shares":3707,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares acquired on March 27, 2022, pursuant to a performance award granted on February 12, 2019, relating to performance during the three-year period ended December 31, 2021."}],"balance_after":13563,"source":{"system":"sec-edgar","filing":"0001127602-22-010503","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760222010503/form4.xml","form_type":"4"}},{"id":2395384,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Restricted Stock Unit","published_at":"2022-02-15T21:42:06.000Z","date":"2022-02-12","kind":"exercise","acquired":false,"shares":317,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The Restricted Stock Units vested in three equal annual installments beginning on February 12, 2020 and are now fully vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The Restricted Stock Units vested in three equal annual installments beginning on February 12, 2020 and are now fully vested."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"This number reflects the aggregate number of Restricted Stock Units held by the reporting person."}],"balance_after":4904,"derivative":{"underlying":"Common Stock","underlying_shares":317},"source":{"system":"sec-edgar","filing":"0001127602-22-005027","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760222005027/form4.xml","form_type":"4"}},{"id":2395383,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Non-qualified Stock Options","published_at":"2022-02-15T21:42:06.000Z","date":"2022-02-11","kind":"grant","acquired":true,"shares":5100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F5","text":"Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option vests in three equal annual installments beginning on the date reflected in this column."}],"balance_after":5100,"derivative":{"exercise_price":276.26,"exercise_date":"2023-02-11","expiration_date":"2032-02-10","underlying":"Common Stock","underlying_shares":5100},"source":{"system":"sec-edgar","filing":"0001127602-22-005027","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760222005027/form4.xml","form_type":"4"}},{"id":2395382,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Restricted Stock Unit","published_at":"2022-02-15T21:42:06.000Z","date":"2022-02-11","kind":"grant","acquired":true,"shares":1450,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Restricted Stock Units vest in three equal annual installments beginning on February 11, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"This number reflects the aggregate number of Restricted Stock Units held by the reporting person."}],"balance_after":5221,"derivative":{"underlying":"Common Stock","underlying_shares":1450},"source":{"system":"sec-edgar","filing":"0001127602-22-005027","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760222005027/form4.xml","form_type":"4"}},{"id":2395381,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2022-02-15T21:42:06.000Z","date":"2022-02-14","kind":"tax_withholding","acquired":false,"shares":108,"price":272.68,"value":29449.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Stock withholding to satisfy tax withholding obligations."}],"balance_after":9856,"source":{"system":"sec-edgar","filing":"0001127602-22-005027","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760222005027/form4.xml","form_type":"4"}},{"id":2395380,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2022-02-15T21:42:06.000Z","date":"2022-02-12","kind":"exercise","acquired":true,"shares":317,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock."}],"balance_after":9964,"source":{"system":"sec-edgar","filing":"0001127602-22-005027","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760222005027/form4.xml","form_type":"4"}},{"id":2408925,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Restricted Stock Unit","published_at":"2022-02-08T16:13:28.000Z","date":"2022-02-04","kind":"exercise","acquired":false,"shares":560,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"This number reflects the aggregate number of Restricted Stock Units held by the reporting person."}],"balance_after":3771,"derivative":{"underlying":"Common Stock","underlying_shares":560},"source":{"system":"sec-edgar","filing":"0001127602-22-003649","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760222003649/form4.xml","form_type":"4"}},{"id":2408924,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2022-02-08T16:13:28.000Z","date":"2022-02-04","kind":"tax_withholding","acquired":false,"shares":165,"price":277.48,"value":45784.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Stock withholding to satisfy tax withholding obligations."}],"balance_after":9647,"source":{"system":"sec-edgar","filing":"0001127602-22-003649","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760222003649/form4.xml","form_type":"4"}},{"id":2408923,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2022-02-08T16:13:28.000Z","date":"2022-02-04","kind":"exercise","acquired":true,"shares":560,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock."}],"balance_after":9812,"source":{"system":"sec-edgar","filing":"0001127602-22-003649","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760222003649/form4.xml","form_type":"4"}},{"id":2412145,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Restricted Stock Unit","published_at":"2022-02-04T14:44:42.000Z","date":"2022-02-02","kind":"exercise","acquired":false,"shares":443,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 2, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 2, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"This number reflects the aggregate number of Restricted Stock Units held by the reporting person."}],"balance_after":4331,"derivative":{"underlying":"Common Stock","underlying_shares":443},"source":{"system":"sec-edgar","filing":"0001127602-22-003279","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760222003279/form4.xml","form_type":"4"}},{"id":2412144,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2022-02-04T14:44:42.000Z","date":"2022-02-02","kind":"tax_withholding","acquired":false,"shares":144,"price":273.18,"value":39337.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Stock withholding to satisfy tax withholding obligations."}],"balance_after":9252,"source":{"system":"sec-edgar","filing":"0001127602-22-003279","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760222003279/form4.xml","form_type":"4"}},{"id":2412143,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2022-02-04T14:44:42.000Z","date":"2022-02-02","kind":"exercise","acquired":true,"shares":443,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock."}],"balance_after":9396,"source":{"system":"sec-edgar","filing":"0001127602-22-003279","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760222003279/form4.xml","form_type":"4"}},{"id":2527283,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Restricted Stock Unit","published_at":"2021-11-03T15:47:40.000Z","date":"2021-11-01","kind":"exercise","acquired":false,"shares":2007,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on November 1, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on November 1, 2020."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"This number reflects the aggregate number of Restricted Stock Units held by the reporting person."}],"balance_after":4774,"derivative":{"underlying":"Common Stock","underlying_shares":2007},"source":{"system":"sec-edgar","filing":"0001127602-21-028237","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760221028237/form4.xml","form_type":"4"}},{"id":2527282,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2021-11-03T15:47:40.000Z","date":"2021-11-01","kind":"tax_withholding","acquired":false,"shares":898,"price":288.78,"value":259324.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Stock withholding to satisfy tax withholding obligations."}],"balance_after":8953,"source":{"system":"sec-edgar","filing":"0001127602-21-028237","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760221028237/form4.xml","form_type":"4"}},{"id":2527281,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2021-11-03T15:47:40.000Z","date":"2021-11-01","kind":"exercise","acquired":true,"shares":2007,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock."}],"balance_after":9851,"source":{"system":"sec-edgar","filing":"0001127602-21-028237","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760221028237/form4.xml","form_type":"4"}},{"id":2721607,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2021-05-10T12:21:44.000Z","date":"2021-05-06","kind":"sale","acquired":false,"shares":2500,"price":276.55,"value":691375.0,"ownership":{"direct":true},"balance_after":7844,"source":{"system":"sec-edgar","filing":"0001127602-21-015959","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760221015959/form4.xml","form_type":"4"}},{"id":2756171,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Restricted Stock Unit","published_at":"2021-04-06T16:18:27.000Z","date":"2021-04-03","kind":"exercise","acquired":false,"shares":1010,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Restricted Stock Units were part of a grant that vested in three equal annual installments beginning on April 3, 2019 and are now fully vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Restricted Stock Units were part of a grant that vested in three equal annual installments beginning on April 3, 2019 and are now fully vested."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"This number reflects the aggregate number of Restricted Stock Units held by the reporting person."}],"balance_after":6781,"derivative":{"underlying":"Common Stock","underlying_shares":1010},"source":{"system":"sec-edgar","filing":"0001127602-21-013315","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760221013315/form4.xml","form_type":"4"}},{"id":2756170,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2021-04-06T16:18:27.000Z","date":"2021-04-03","kind":"tax_withholding","acquired":false,"shares":452,"price":252.67,"value":114206.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Stock withholding to satisfy tax withholding obligations."}],"balance_after":10344,"source":{"system":"sec-edgar","filing":"0001127602-21-013315","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760221013315/form4.xml","form_type":"4"}},{"id":2756169,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2021-04-06T16:18:27.000Z","date":"2021-04-03","kind":"exercise","acquired":true,"shares":1010,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock."}],"balance_after":10796,"source":{"system":"sec-edgar","filing":"0001127602-21-013315","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760221013315/form4.xml","form_type":"4"}},{"id":2768555,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2021-03-30T22:42:34.000Z","date":"2021-03-27","kind":"tax_withholding","acquired":false,"shares":790,"price":251.58,"value":198748.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Stock withholding to satisfy tax withholding obligations."}],"balance_after":9786,"source":{"system":"sec-edgar","filing":"0001127602-21-012362","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760221012362/form4.xml","form_type":"4"}},{"id":2768554,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2021-03-30T22:42:34.000Z","date":"2021-03-27","kind":"grant","acquired":true,"shares":2104,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares acquired on March 27, 2021, pursuant to a performance award granted on February 12, 2018, relating to performance during the three-year period ended December 31, 2020."}],"balance_after":10576,"source":{"system":"sec-edgar","filing":"0001127602-21-012362","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760221012362/form4.xml","form_type":"4"}},{"id":2856073,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Restricted Stock Unit","published_at":"2021-02-17T21:25:50.000Z","date":"2021-02-12","kind":"exercise","acquired":false,"shares":317,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"This number reflects the aggregate number of Restricted Stock Units held by the reporting person."}],"balance_after":7791,"derivative":{"underlying":"Common Stock","underlying_shares":317},"source":{"system":"sec-edgar","filing":"0001127602-21-006177","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760221006177/form4.xml","form_type":"4"}},{"id":2856072,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Restricted Stock Unit","published_at":"2021-02-17T21:25:50.000Z","date":"2021-02-12","kind":"exercise","acquired":false,"shares":264,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2019 and are now fully vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2019 and are now fully vested."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"This number reflects the aggregate number of Restricted Stock Units held by the reporting person."}],"balance_after":8108,"derivative":{"underlying":"Common Stock","underlying_shares":264},"source":{"system":"sec-edgar","filing":"0001127602-21-006177","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760221006177/form4.xml","form_type":"4"}},{"id":2856071,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2021-02-17T21:25:50.000Z","date":"2021-02-12","kind":"tax_withholding","acquired":false,"shares":93,"price":238.26,"value":22158.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Stock withholding to satisfy tax withholding obligations."}],"balance_after":8472,"source":{"system":"sec-edgar","filing":"0001127602-21-006177","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760221006177/form4.xml","form_type":"4"}},{"id":2856070,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2021-02-17T21:25:50.000Z","date":"2021-02-12","kind":"exercise","acquired":true,"shares":317,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock."}],"balance_after":8565,"source":{"system":"sec-edgar","filing":"0001127602-21-006177","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760221006177/form4.xml","form_type":"4"}},{"id":2856069,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2021-02-17T21:25:50.000Z","date":"2021-02-12","kind":"tax_withholding","acquired":false,"shares":87,"price":238.26,"value":20728.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Stock withholding to satisfy tax withholding obligations."}],"balance_after":8248,"source":{"system":"sec-edgar","filing":"0001127602-21-006177","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760221006177/form4.xml","form_type":"4"}},{"id":2856068,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2021-02-17T21:25:50.000Z","date":"2021-02-12","kind":"exercise","acquired":true,"shares":264,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock."}],"balance_after":8335,"source":{"system":"sec-edgar","filing":"0001127602-21-006177","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760221006177/form4.xml","form_type":"4"}},{"id":2875251,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Restricted Stock Unit","published_at":"2021-02-08T20:39:09.000Z","date":"2021-02-04","kind":"exercise","acquired":false,"shares":560,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 4, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"This number reflects the aggregate number of Restricted Stock Units held by the reporting person."}],"balance_after":8372,"derivative":{"underlying":"Common Stock","underlying_shares":560},"source":{"system":"sec-edgar","filing":"0001127602-21-004346","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760221004346/form4.xml","form_type":"4"}},{"id":2875250,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2021-02-08T20:39:09.000Z","date":"2021-02-04","kind":"tax_withholding","acquired":false,"shares":187,"price":223.78,"value":41846.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Stock withholding to satisfy tax withholding obligations."}],"balance_after":8071,"source":{"system":"sec-edgar","filing":"0001127602-21-004346","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760221004346/form4.xml","form_type":"4"}},{"id":2875249,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2021-02-08T20:39:09.000Z","date":"2021-02-04","kind":"exercise","acquired":true,"shares":560,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock."}],"balance_after":8258,"source":{"system":"sec-edgar","filing":"0001127602-21-004346","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760221004346/form4.xml","form_type":"4"}},{"id":2879698,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Non-qualified Stock Options","published_at":"2021-02-04T22:14:42.000Z","date":"2021-02-02","kind":"grant","acquired":true,"shares":4600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests in three equal annual installments beginning on the date reflected in this column."}],"balance_after":4600,"derivative":{"exercise_price":233.39,"exercise_date":"2022-02-02","expiration_date":"2031-02-01","underlying":"Common Stock","underlying_shares":4600},"source":{"system":"sec-edgar","filing":"0001127602-21-004004","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760221004004/form4.xml","form_type":"4"}},{"id":2879697,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Restricted Stock Unit","published_at":"2021-02-04T22:14:42.000Z","date":"2021-02-02","kind":"grant","acquired":true,"shares":1330,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Restricted Stock Units vest in three equal annual installments beginning on February 2, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Restricted Stock Units vest in three equal annual installments beginning on February 2, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This number reflects the aggregate number of Restricted Stock Units held by the reporting person."}],"balance_after":8932,"derivative":{"underlying":"Common Stock","underlying_shares":1330},"source":{"system":"sec-edgar","filing":"0001127602-21-004004","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760221004004/form4.xml","form_type":"4"}},{"id":2990371,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2020-11-06T14:06:09.000Z","date":"2020-11-04","kind":"sale","acquired":false,"shares":1500,"price":214.1357,"value":321203.55,"ownership":{"direct":true},"balance_after":7698,"source":{"system":"sec-edgar","filing":"0001127602-20-028306","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760220028306/form4.xml","form_type":"4"}},{"id":2993388,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Restricted Stock Unit","published_at":"2020-11-04T22:40:08.000Z","date":"2020-11-02","kind":"exercise","acquired":false,"shares":2006,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on November 1, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on November 1, 2020."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"This number reflects the aggregate number of Restricted Stock Units held by the reporting person."}],"balance_after":7602,"derivative":{"underlying":"Common Stock","underlying_shares":2006},"source":{"system":"sec-edgar","filing":"0001127602-20-028182","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760220028182/form4.xml","form_type":"4"}},{"id":2993387,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2020-11-04T22:40:08.000Z","date":"2020-11-02","kind":"tax_withholding","acquired":false,"shares":895,"price":207.23,"value":185470.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Stock withholding to satisfy tax withholding obligations."}],"balance_after":9198,"source":{"system":"sec-edgar","filing":"0001127602-20-028182","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760220028182/form4.xml","form_type":"4"}},{"id":2993386,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2020-11-04T22:40:08.000Z","date":"2020-11-02","kind":"exercise","acquired":true,"shares":2006,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock."}],"balance_after":9198,"source":{"system":"sec-edgar","filing":"0001127602-20-028182","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760220028182/form4.xml","form_type":"4"}},{"id":3181159,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Restricted Stock Unit","published_at":"2020-04-07T20:21:37.000Z","date":"2020-04-03","kind":"exercise","acquired":false,"shares":1010,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on April 3, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on April 3, 2019."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"This number reflects the aggregate number of Restricted Stock Units held by the reporting person."}],"balance_after":9608,"derivative":{"underlying":"Common Stock","underlying_shares":1010},"source":{"system":"sec-edgar","filing":"0001127602-20-013389","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760220013389/form4.xml","form_type":"4"}},{"id":3181158,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2020-04-07T20:21:37.000Z","date":"2020-04-03","kind":"tax_withholding","acquired":false,"shares":372,"price":113.31,"value":42151.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Stock withholding to satisfy tax withholding obligations."}],"balance_after":8087,"source":{"system":"sec-edgar","filing":"0001127602-20-013389","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760220013389/form4.xml","form_type":"4"}},{"id":3181157,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2020-04-07T20:21:37.000Z","date":"2020-04-03","kind":"exercise","acquired":true,"shares":1010,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":8459,"source":{"system":"sec-edgar","filing":"0001127602-20-013389","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760220013389/form4.xml","form_type":"4"}},{"id":3189711,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2020-04-01T18:29:58.000Z","date":"2020-03-30","kind":"tax_withholding","acquired":false,"shares":1014,"price":131.95,"value":133797.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Stock withholding to satisfy tax withholding obligations."}],"balance_after":7449,"source":{"system":"sec-edgar","filing":"0001127602-20-012377","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760220012377/form4.xml","form_type":"4"}},{"id":3189710,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2020-04-01T18:29:58.000Z","date":"2020-03-30","kind":"grant","acquired":true,"shares":3402,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares acquired on March 30, 2020, pursuant to a performance award granted on February 7, 2017, relating to performance during the three-year period ended December 31, 2019."}],"balance_after":8463,"source":{"system":"sec-edgar","filing":"0001127602-20-012377","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760220012377/form4.xml","form_type":"4"}},{"id":3271881,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Restricted Stock Unit","published_at":"2020-02-14T20:48:43.000Z","date":"2020-02-12","kind":"exercise","acquired":false,"shares":316,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"This number reflects the aggregate number of Restricted Stock Units held by the reporting person."}],"balance_after":10618,"derivative":{"underlying":"Common Stock","underlying_shares":316},"source":{"system":"sec-edgar","filing":"0001127602-20-005602","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760220005602/form4.xml","form_type":"4"}},{"id":3271880,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Restricted Stock Unit","published_at":"2020-02-14T20:48:43.000Z","date":"2020-02-12","kind":"exercise","acquired":false,"shares":263,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2019."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"This number reflects the aggregate number of Restricted Stock Units held by the reporting person."}],"balance_after":10934,"derivative":{"underlying":"Common Stock","underlying_shares":263},"source":{"system":"sec-edgar","filing":"0001127602-20-005602","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760220005602/form4.xml","form_type":"4"}},{"id":3271879,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2020-02-14T20:48:43.000Z","date":"2020-02-12","kind":"tax_withholding","acquired":false,"shares":88,"price":187.51,"value":16500.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Stock withholding to satisfy tax withholding obligations."}],"balance_after":5061,"source":{"system":"sec-edgar","filing":"0001127602-20-005602","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760220005602/form4.xml","form_type":"4"}},{"id":3271878,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2020-02-14T20:48:43.000Z","date":"2020-02-12","kind":"exercise","acquired":true,"shares":316,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock."}],"balance_after":5149,"source":{"system":"sec-edgar","filing":"0001127602-20-005602","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760220005602/form4.xml","form_type":"4"}},{"id":3271877,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2020-02-14T20:48:43.000Z","date":"2020-02-12","kind":"tax_withholding","acquired":false,"shares":71,"price":187.51,"value":13313.21,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Stock withholding to satisfy tax withholding obligations."}],"balance_after":4833,"source":{"system":"sec-edgar","filing":"0001127602-20-005602","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760220005602/form4.xml","form_type":"4"}},{"id":3271876,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2020-02-14T20:48:43.000Z","date":"2020-02-12","kind":"exercise","acquired":true,"shares":263,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock."}],"balance_after":4904,"source":{"system":"sec-edgar","filing":"0001127602-20-005602","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760220005602/form4.xml","form_type":"4"}},{"id":3280399,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Restricted Stock Unit","published_at":"2020-02-11T18:43:49.000Z","date":"2020-02-07","kind":"exercise","acquired":false,"shares":337,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2018 and are now fully vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Restricted Stock Units vested in three equal annual installments beginning on February 7, 2018 and are now fully vested."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"This number reflects the aggregate number of Restricted Stock Units held by the reporting person."}],"balance_after":11197,"derivative":{"underlying":"Common Stock","underlying_shares":337},"source":{"system":"sec-edgar","filing":"0001127602-20-004807","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760220004807/form4.xml","form_type":"4"}},{"id":3280398,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2020-02-11T18:43:49.000Z","date":"2020-02-07","kind":"tax_withholding","acquired":false,"shares":103,"price":182.33,"value":18779.99,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Stock withholding to satisfy tax withholding obligations."}],"balance_after":4641,"source":{"system":"sec-edgar","filing":"0001127602-20-004807","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760220004807/form4.xml","form_type":"4"}},{"id":3280397,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Common Stock","published_at":"2020-02-11T18:43:49.000Z","date":"2020-02-07","kind":"exercise","acquired":true,"shares":337,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock."}],"balance_after":4744,"source":{"system":"sec-edgar","filing":"0001127602-20-004807","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760220004807/form4.xml","form_type":"4"}},{"id":3287136,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Non-qualified Stock Options","published_at":"2020-02-06T19:33:08.000Z","date":"2020-02-04","kind":"grant","acquired":true,"shares":7300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F4","text":"Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests in three equal annual installments beginning on the date reflected in this column."}],"balance_after":7300,"derivative":{"exercise_price":182.51,"exercise_date":"2021-02-04","expiration_date":"2030-02-03","underlying":"Common Stock","underlying_shares":7300},"source":{"system":"sec-edgar","filing":"0001127602-20-003950","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760220003950/form4.xml","form_type":"4"}},{"id":3287135,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Restricted Stock Unit","published_at":"2020-02-06T19:33:08.000Z","date":"2020-02-04","kind":"grant","acquired":true,"shares":1680,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Restricted Stock Units vest in three equal annual installments beginning on February 4, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Restricted Stock Units vest in three equal annual installments beginning on February 4, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This number reflects the aggregate number of Restricted Stock Units held by the reporting person."}],"balance_after":11534,"derivative":{"underlying":"Common Stock","underlying_shares":1680},"source":{"system":"sec-edgar","filing":"0001127602-20-003950","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760220003950/form4.xml","form_type":"4"}},{"id":3380857,"issuer":{"id":1277,"kind":"organization","name":"LABCORP HOLDINGS INC.","symbol":"LH"},"owners":[{"id":113219,"kind":"person","name":"Kirchgraber Paul R","position":1,"cik":"0001791393","reported_name":"Kirchgraber Paul R","relationship":{"officer":true,"officer_title":"CEO, Covance Drug Development"}}],"security":"Restricted Stock Unit","published_at":"2019-11-06T01:14:06.000Z","date":"2019-11-01","kind":"grant","acquired":true,"shares":6020,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Restricted Stock Units vest in three equal annual installments beginning on 11/1/2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Restricted Stock Units vest in three equal annual installments beginning on 11/1/2020."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"This number reflects the aggregate number of Restricted Stock Units held by the reporting person."}],"balance_after":9854,"derivative":{"underlying":"Common Stock","underlying_shares":6020},"source":{"system":"sec-edgar","filing":"0001127602-19-031973","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/920148/000112760219031973/form4.xml","form_type":"4"}}]}